Eligibilty

Gender



Age Group



More options for age range

Dates

Names

Showing 1 - 5 of 32 results
Page 1 of 7   

this study is for patients diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL).

Principal Investigator: Ayman El-Sheikh, MD

Department:Hematology/Oncology

This research study is for patients diagnosed with T-cell Acute Lymphoblastic Leukemia (ALL).  ALL is a type of cancer that occurs in the bone marrow.  It is a disease in which there is an uncontrolled growth of abnormal white blood cells, referred to as blasts.  These abnormal cells crowd out the normal cells in the bone marrow.  Sometimes these blasts cells can be found in the brain, spinal cord, and /or other organs of the body.  Participants in this study have a type of ALL that places them in the Intermediate Risk group of T-cell ALL, which means that they have entered remission (less than 5% blasts in the bone marrow at the end of Induction therapy and 0.1-1% blasts detected by a test called flow cytometry) and are not in the Low or High Risk groups. Most subjects (about 60%) with T-cell ALL fall into the Intermediate Risk group.

 

age group:1 to 30 years trial start date:May 29, 2008
Gender Preference:none Trial End Date: May 29, 2018
Contact Info:

Julie de la Garza, (319) 356-3749

Keywords: 200710790 ; Acute Lymphoblastic Leukemia ; ALL ; cancer ; El-Sheikh ; leukemia ; lymphoma ; pediatric ; phase three ; T-cell Lymphoblastic Lymphoma

Brain Study

Principal Investigator:Daniel O'Leary, PhD

Department:Department or Field of Study

Adolescents between the ages of 13-18 (who are still in jr. high or high school) with no family history of alcohol problems are invited to participate in a research study investigating brain development conducted at the Department of Psychiatry. 

Study will last 1-2 visits and involve filling out forms, saliva sample, cognitive testing and an MRI scan (no radiation).  Parents will be asked to fill out family history forms.  Additionally, both parents should have no more than a 4 year college degree.  Compensation available. 

For more information, call (319) 353-8520 or email brain-lab@uiowa.edu

age group:13 to 18 years trial start date:January 1, 2014
Gender Preference:none Trial End Date: January 1, 2015
Contact Info:

Call (319) 353-8520 or email brain-lab@uiowa.edu

Keywords: brain development ; pediatric ; psychiatry ; substance use and addictive disorders

Brain Study

Principal Investigator: Daniel O'Leary, PhD

Department:Psychiatry

Adolescents between the ages of 13-18  (who are still in jr. high/high school) with at least 1 biological parent who has a history of alcohol treatment/addiction/problems related to use are invited to participate in a research study investigating brain development conducted at the Department of Psychiatry.  

Study will last 1-2 visits and involves filling out forms, saliva sample, cognitive testing and an MRI scan (no radiation).  Guardians will be asked to fill out family history forms.  Compensation available.  For more information, call (319) 353-8520 or email brain-lab@uiowa.edu

This study is being conducted by the University of Iowa Department of Psychiatry.

age group:13 to 18 years trial start date:January 1, 2014
Gender Preference:none Trial End Date: January 1, 2015
Contact Info:

E-mail: brain-lab@uiowa.edu

Phone Number: 319-353-8520

Toll Free Number: 1-877-575-2864



Keywords: brain development ; pediatric ; psychiatry ; substance use and addictive disorders

ACNS0331

Principal Investigator:Ayman El-Sheikh, MD

Department:Department or Field of Study

The main purpose of this study is to find out if reducing the overall dose of radiation to the brain and spine will reduce rates of survival in children with medulloblastoma.  The study will also look at whether reducing the volume of radiation given during the boost will reduce survival rates in children with medulloblastoma.

age group:3 to 22 years trial start date:January 18, 2005
Gender Preference:none Trial End Date: January 18, 2015
Contact Info:

Julie de la Garza, (319) 356-3749

Keywords: 200410785 ; cancer ; El-Sheikh ; medulloblastoma ; pediatric ; phase three

Oral LDE225 Versus Temozolomide in Patients With Hh-pathway Activated Relapsed Medulloblastoma

Principal Investigator: Sue O'Dorisio, MD, PhD

Department:Pediatrics Academic Administration

Participants in this research study have relapsed medulloblastoma and will receive the drug LDE225 or Temozolomide. The purpose of the study is to find out if the drug LDE225 is safe and has more beneficial effects in people who have relapsed medulloblastoma compared to the drug Temozolomide. LDE225 is an investigational drug being developed by Novartis, the Sponsor, for the treatment of cancer. Temozolomide is a medication that is indicated for the treatment of patients with certain brain tumors.

About 109 patients from about 89 sites in North America, Europe, Australia and Latin America will be enrolled into this study.

age group:0 to 99 years trial start date:December 12, 2013
Gender Preference:none Trial End Date: January 1, 2018
Contact Info:

Joan Kempf, (319) 384-5280

Keywords: 201304508 ; cancer ; medulloblastoma ; O ; pediatric ; Phase three
Page 1 of 7
« 1 2 3 4 5  ... » 
Results per page
5 | 15 | 25

Clinical Research Studies

Filter By Started within
Show trials started in last 1 month
Your Selections

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks

x